Cymbalta for chronic pain
Executive Summary
Eli Lilly submits supplemental new drug application in the second quarter for Cymbalta (duloxetine) in the management of chronic pain, the firm announces May 29. With an expected 10-month review, the drug's likely PDUFA timeframe would be February to March 2009. The drug was approved for acute and maintenance treatment of major depressive disorder Nov. 30; it is also approved for acute treatment of generalized anxiety disorder and management of diabetic peripheral neuropathic pain, all in adults 18 and older. An sNDA for use of the drug in fibromylagia is under FDA review, with an expected PDUFA data in June
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.